Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
dolutegravir/abacavir/lamivudine (Triumeq®)
Reference No. 2365
Publication date:
20/05/2015
Last review date:
27/03/2018
Appraisal information
dolutegravir/abacavir/lamivudine (Triumeq®) 50 mg/600 mg/300 mg film-coated tablet
Company:
ViiV Healthcare UK Ltd
BNF category:
Infections
NMG meeting date:
25/02/2015
AWMSG meeting date:
25/03/2015
Submission Type:
Limited Submission
Status:
Recommended
Advice No:
0415
Ratification by Welsh Government:
15/05/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Dolutegravir/abacavir/lamivudine (Triumeq®) is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
dolutegravir_abacavir_lamivudine (Triumeq) 2365 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
dolutegravir abacavir lamivudine (Triumeq) 2365 ASAR
Clinical Expert (CE) Summary
Download
dolutegravir abacavir lamivudine (Triumeq) 2365 CE summary